136 related articles for article (PubMed ID: 37897456)
1. SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction.
Avula V; Sharma G; Kosiborod MN; Vaduganathan M; Neilan TG; Lopez T; Dent S; Baldassarre L; Scherrer-Crosbie M; Barac A; Liu J; Deswal A; Khadke S; Yang EH; Ky B; Lenihan D; Nohria A; Dani SS; Ganatra S
JACC Heart Fail; 2024 Jan; 12(1):67-78. PubMed ID: 37897456
[TBL] [Abstract][Full Text] [Related]
2. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
Yang S; Zhao L; Mi Y; He W
Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
[TBL] [Abstract][Full Text] [Related]
3. Utilization rates and predictors of sodium glucose cotransporter 2 inhibitor use in patients with heart failure with or without type 2 diabetes.
Bermudez SR; Anderson JR; Bos AJ; Ray GM
Am J Health Syst Pharm; 2023 Dec; 80(24):1787-1795. PubMed ID: 37551996
[TBL] [Abstract][Full Text] [Related]
4. Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database.
Fawzy AM; Rivera-Caravaca JM; Underhill P; Fauchier L; Lip GYH
Diabetes Obes Metab; 2023 Feb; 25(2):602-610. PubMed ID: 36054168
[TBL] [Abstract][Full Text] [Related]
5. Contemporary use of SGLT2 inhibitors in heart failure patients with diabetes mellitus: a comparison of DPP4 inhibitors in a nationwide electric health database of the superaged society.
Nakai M; Iwanaga Y; Kanaoka K; Sumita Y; Nishioka Y; Myojin T; Kubo S; Okada K; Soeda T; Noda T; Sakata Y; Imamura T; Saito Y; Yasuda S; Miyamoto Y
Cardiovasc Diabetol; 2022 Aug; 21(1):157. PubMed ID: 35964039
[TBL] [Abstract][Full Text] [Related]
6. Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure.
Chen K; Nie Z; Shi R; Yu D; Wang Q; Shao F; Wu G; Wu Z; Chen T; Li C
JAMA Netw Open; 2023 Aug; 6(8):e2330754. PubMed ID: 37615988
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
[TBL] [Abstract][Full Text] [Related]
8. Stabilization of kidney function and reduction in heart failure events with sodium-glucose co-transporter 2 inhibitors: A meta-analysis and meta-regression analysis.
Keidai Y; Yoshiji S; Hasebe M; Minamino H; Murakami T; Tanaka D; Fujita Y; Inagaki N
Diabetes Obes Metab; 2023 Sep; 25(9):2505-2513. PubMed ID: 37217461
[TBL] [Abstract][Full Text] [Related]
9. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
Rampersad C; Kraut E; Whitlock RH; Komenda P; Woo V; Rigatto C; Tangri N
Am J Kidney Dis; 2020 Oct; 76(4):471-479.e1. PubMed ID: 32464161
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
[TBL] [Abstract][Full Text] [Related]
11. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study.
Pasternak B; Ueda P; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Wintzell V; Melbye M; Svanström H
BMJ; 2019 Aug; 366():l4772. PubMed ID: 31467044
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
[TBL] [Abstract][Full Text] [Related]
13. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis.
Bhattarai M; Salih M; Regmi M; Al-Akchar M; Deshpande R; Niaz Z; Kulkarni A; Siddique M; Hegde S
JAMA Netw Open; 2022 Jan; 5(1):e2142078. PubMed ID: 34985519
[TBL] [Abstract][Full Text] [Related]
14. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
Heerspink HJL; Karasik A; Thuresson M; Melzer-Cohen C; Chodick G; Khunti K; Wilding JPH; Garcia Rodriguez LA; Cea-Soriano L; Kohsaka S; Nicolucci A; Lucisano G; Lin FJ; Wang CY; Wittbrodt E; Fenici P; Kosiborod M
Lancet Diabetes Endocrinol; 2020 Jan; 8(1):27-35. PubMed ID: 31862149
[TBL] [Abstract][Full Text] [Related]
15. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
;
Lancet; 2022 Nov; 400(10365):1788-1801. PubMed ID: 36351458
[TBL] [Abstract][Full Text] [Related]
16. SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis.
Barbarawi M; Al-Abdouh A; Barbarawi O; Lakshman H; Al Kasasbeh M; Chen K
Heart Fail Rev; 2022 May; 27(3):951-960. PubMed ID: 33620621
[TBL] [Abstract][Full Text] [Related]
17. Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan.
Chung MC; Hung PH; Hsiao PJ; Wu LY; Chang CH; Wu MJ; Shieh JJ; Chung CJ
JAMA Netw Open; 2021 Nov; 4(11):e2135353. PubMed ID: 34797368
[TBL] [Abstract][Full Text] [Related]
18. Effect of Sodium-Glucose Cotransporter Inhibitors on Major Adverse Cardiovascular Events and Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus and Atrial Fibrillation.
Kwon CH; Kim YJ; Kim MJ; Cha MJ; Cho MS; Nam GB; Choi KJ; Kim J
Am J Cardiol; 2022 Sep; 178():35-42. PubMed ID: 35810007
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care.
Fralick M; Schneeweiss S; Redelmeier DA; Razak F; Gomes T; Patorno E
Diabetes Obes Metab; 2021 Oct; 23(10):2320-2328. PubMed ID: 34169619
[TBL] [Abstract][Full Text] [Related]
20. Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.
Usman MS; Siddiqi TJ; Anker SD; Bakris GL; Bhatt DL; Filippatos G; Fonarow GC; Greene SJ; Januzzi JL; Khan MS; Kosiborod MN; McGuire DK; Piña IL; Rosenstock J; Vaduganathan M; Verma S; Zieroth S; Butler J
J Am Coll Cardiol; 2023 Jun; 81(25):2377-2387. PubMed ID: 37344038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]